Amila Silva, MD
Ophthalmology · Stanford, CANPI 1083855670
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,350 of the $23,684 with a category attached, or 90.1%. Alcon Research LLC accounts for 81.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $13,500 and has fallen 93.6% since, to $862 in 2024. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $382.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$19K
- Alcon$3K
- Genentech USA, Inc.$431
- Regeneron Healthcare Solutions, Inc.$306
- Alimera Sciences, Inc.$228
- AbbVie$226
- plus $220 from 6 others
What the payments were for
- Consulting fees$21,35090%
- Travel & lodging$7343%
- Food & beverage$1,6007%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 19 | $19,342 |
| Alcon | 2 | $2,931 |
| Genentech USA, Inc. | 11 | $431 |
| Regeneron Healthcare Solutions, Inc. | 11 | $306 |
| Alimera Sciences, Inc. | 7 | $228 |
| AbbVie(2 entities) | 6 | $226 |
| Apellis Pharmaceuticals, Inc. | 1 | $128 |
| Novartis | 1 | $24 |
| Genentech, Inc. | 1 | $21 |
| Summit Surgical Corp. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,684 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 187 | $9,593 |
| Brimonidine Tartrate | 31 | $2,663 |
| Ketorolac Tromethamine | 50 | $1,918 |
| Fluorometholone | 15 | $844 |
| Acetazolamide | 13 | $764 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 56 | $712 |
| MoxifloxacinMoxifloxacin Hcl | 33 | $623 |
| Latanoprost | 65 | $622 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 82 | $541 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $243 |
| Timolol Maleate | 15 | $168 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Stanford
- Kuldev SinghStanford$1.5M
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.